We are live on ! Find out more
CRDL

Cardiol Therapeutics
CRDL

35 hedge funds and large institutions have $3.54M invested in Cardiol Therapeutics in 2023 Q1 according to their latest regulatory filings, with 10 funds opening new positions, 4 increasing their positions, 6 reducing their positions, and 7 closing their positions.

New
Increased
Maintained
Reduced
Closed

43% more first-time investments, than exits

New positions opened: 10 | Existing positions closed: 7

9% more funds holding

Funds holding: 32 → 35 (+3)

0.53% more ownership

Funds ownership: 10.8% → 11.32% (+0.53%)

3% less capital invested

Capital invested by funds: $3.64M → $3.54M (-$95.1K)

33% less repeat investments, than reductions

Existing positions increased: 4 | Existing positions reduced: 6

Holders
35
Holders Change
+3
Holders Change %
+9.38%
% of All Funds
0.56%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
10
Increased
4
Reduced
6
Closed
7
Calls
$2K
Puts
–
Net Calls
+$2K
Net Calls Change
-$31K

Top Buyers

Rank Fund Capital Flow
1
AI
AXS Investments
New York
+$1.02M
2
Susquehanna International Group
Susquehanna International Group
Pennsylvania
+$63K
3
AI
AdvisorShares Investments
Maryland
+$46.7K
4
LNWTC
Laird Norton Wetherby Trust Company
Washington
+$36.3K
5
Bank of America
Bank of America
North Carolina
+$35.8K

Top Sellers

Rank Fund Capital Flow
1
Mirae Asset Global Investments
Mirae Asset Global Investments
South Korea
-$557K
2
MI
MMCAP International
Cayman Islands
-$118K
3
VIA
Vident Investment Advisory
Georgia
-$74.8K
4
Goldman Sachs
Goldman Sachs
New York
-$45.5K
5
Jane Street
Jane Street
New York
-$25K
Name Holding Trade Value Shares
Change 		Change in
Stake
National Bank of Canada
26
National Bank of Canada
Quebec, Canada
$977 +$1.18K +2,000 New
FDCDDQ
27
Federation des caisses Desjardins du Quebec
Quebec, Canada
$878 -$1.77K -3,000 -63%
RA
28
Rise Advisors
New York
$487 – – –
SC
29
SouthState Corp
Florida
$487 – – –
NC
30
NewSquare Capital
Pennsylvania
$341 – – –
OLVIG
31
Oliver Lagore Vanvalin Investment Group
Michigan
$244 – – –
PNC Financial Services Group
32
PNC Financial Services Group
Pennsylvania
$49 +$59 +100 New
Mirae Asset Global Investments
33
Mirae Asset Global Investments
South Korea
– -$557K -1,094,040 Closed
VIA
34
Vident Investment Advisory
Georgia
– -$74.8K -146,807 Closed
TSS
35
Two Sigma Securities
New York
– -$17.1K -33,564 Closed
TRCT
36
Tower Research Capital (TRC)
New York
– -$11K -22,456 Closed
SG
37
StoneX Group
New York
– -$5.4K -10,586 Closed
Morgan Stanley
38
Morgan Stanley
New York
– -$2.29K -4,482 Closed
TCM
39
Tradewinds Capital Management
Washington
– -$255 -500 Closed
Toronto Dominion Bank
40
Toronto Dominion Bank
Ontario, Canada
– +$340 +575 New
1
2

CRDL Hedge Fund Activity: Q1 2023 in Review

35 of the 6,275 institutional investors tracked by Wall St. Rank reported a position in Cardiol Therapeutics (CRDL) for Q1 2023, worth a combined $3.54M — down 2.6% from $3.64M a quarter earlier.

Buyers outnumbered sellers: 10 funds opened new CRDL positions and 7 closed out — a net gain of 3 holders — while 4 added to existing stakes and 6 trimmed.

The largest buyer was AXS Investments, opening a new position worth an estimated $1.02M. The largest seller was Mirae Asset Global Investments, exiting entirely with an estimated $557K sold.

  • 35 institutional investors held Cardiol Therapeutics (CRDL) as of Q1 2023, up from 32 in Q4 2022.
  • Funds reported $3.54M of Cardiol Therapeutics stock for Q1 2023, down 2.6% quarter-over-quarter.
  • 10 funds opened new Cardiol Therapeutics positions in Q1 2023 and 7 closed out, a net change of +3 holders.
  • The largest Cardiol Therapeutics buyer in Q1 2023 was AXS Investments, an estimated $1.02M added.
  • The largest Cardiol Therapeutics seller in Q1 2023 was Mirae Asset Global Investments, an estimated $557K sold.

Based on aggregated 13F filings for Q1 2023.